Saratov JOURNAL of Medical and Scientific Research

Evaluation of efficiency of tactics to improve the preterm birth results (review)

Year: 2020, volume 16 Issue: №1 Pages: 17-23
Heading: Obstetrics and Gynecology Article type: Review
Authors: Yakovleva O.V., Glukhova T.N., Rogozhina I.E.
Organization: Saratov State Medical University

The review is devoted to the assessment of the effectiveness of measures to improve the outcome of preterm birth. An analysis of randomized multicenter studies from 2014 to 2019 of the database of the National Library of Medicine PubMed was carried out. Information is presented on the effectiveness of the prevention of respiratory distress syndrome, tocolytic therapy, neuroprotection of the fetus, systemic antibacterial therapy.

1. Berger R, Abele H, Bahlmann F, et al. Prevention and therapy of preterm birth: Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry Number 015/025, February 2019): Part 1 with recommendations on the epidemiology etiology, prediction, primary and secondary prevention of preterm birth. Geburtshilfe Frauenheilkd 2019; 79 (8): 800-12. DOI: 10.1055/a-0903-2671.
2. American College of Obstetricians and Gynecologists' Committee on practice bulletins-obstetrics: Practice bulletin No. 171: Management of preterm labor. Obstet Gynecol 2016; 128 (4): 155-64. DOI: 10.1097/AOG. 0000000000001711.
3. Rundell K, Panchal B. Preterm labor: prevention and management. Am Fam Physician 2017; 95 (6): 366-72.
4. Haram K, Mortensen JH, Magann EF, et al. Antenatal corticosteroid treatment: factors other than lung maturation. J Matern Fetal Neonatal Med 2017; 30 (12): 1437-41. DOI: 10.108 0/14767058.2016.1219716. Epub 2016 Aug 30.
5. American College of Obstetricians and Gynecologists: Antenatal corticosteroid therapy for fetal maturation: Committee opinion No. 713. Obstet Gynecol 2017; 130: 102-9. URL: https:// / Antenatal-Corticosteroid-Therapy-for-Fetal-Maturation.
6. LauHCQ, Tung JSZ, Wong TTC,etal. Timing of antenatal steroids exposure and its effects on neonates. Arch Gynec Obstet 2017; 296 (6): 1091-6. DOI: 10.1007/s00404-017-4543-1. Epub 2017Sep25.
7. Boutin SA, Bujold A, Burrows E, et al. No. 364-Antenatal corticosteroid therapy for improving neonatal outcomes. J Obstet Gynaecol Canada 2018; 40 (9): 1219-39. URL: https:// jogc. 2018.04.018.
8. Gyamfi-Bannerman C, Thorn EA, Blackwell SC, et al. Antenatal betamethasone for women at risk for late preterm delivery. N Engl J Med 2016; 374 (14): 1311-20. DOI: 10.1056/NEJMoa1516783.
9. Souter V, Kauffman E, Marshall AJ, et al. Assessing the potential impact of extending antenatal steroids to the late preterm period. Am J Obstet Gynecol 2017; 217 (4): 461-7. URL: https://doi.Org/10.1016/j. ajog. 2017.04.029.
10. Amiya RM, Mlunde LB, Ota E, et al. Antenatal corticosteroids for reducing adverse maternal and child outcomes in special populations of women at risk of imminent preterm birth: a systematic review and meta-analysis. PLoS ONE 2016; 11 (2): 0147604. URL: pone. 0147604.
11. Schmitz T. Prevention of preterm birth complications by antenatal corticosteroid administration. J Gynecol Obstet Biol Reprod (Paris) 2016; 45 (10): 1399-417. DOI: 10.1016/j. jgyn. 2016.09.008. Epub 2016 Oct 21.
12. Lyon C, Bello JK. Steroids during late preterm labor: better later than never. J Fam Pract 2017; 66 (2): 104-6. URL:
13. WHO recommendation on use of either dexamethasone or betamethasone as the antenatal corticosteroid of choice/The WHO Reproductive Health Library. Geneva: World Health Organization, 2015. URL: https:// ption-pregnancy-childbirth-a nd-post part um-ca re /pregnancy-corn plications / preterm- birth/who-recommendation-use-either-dexamethasone-or-betamethasone-antenatal-corticosteroid-choice.
14. WHO recommendation on use of a single repeat course of antenatal corticosteroid/The WHO Reproductive Health Library. Geneva: World Health Organization, 2015. URL: https:// /pregnancy-cornplications/preterm-birth/who-recommendation-use-single-repeat-course-antenatal-corticosteroid.
15. WHO recommendation on antenatal corticosteroid therapy in women undergoing planned caesarean section at late preterm gestations (34-36+6 weeks)/The WHO Reproductive Health Library. Geneva: World Health Organization, 2015. URL: na n cy-ch i Id birth-a nd-post part um-ca re / pregnancy-complications/preterm-birth/who-recommendation-antenatal-corticosteroid-therapy-women-undergoing-planned-caesarean-section-late.
16. Doret M, Kayem G. Tocolysis for preterm labor without premature preterm rupture of membranes. J Gynecol Obstet Biol Reprod (Paris) 2016; 45 (10): 1374-98. DOI: 10.1016/j. jgyn. 2016.09.018. Epub 2016 Oct 28.
17. WHO recommendation on the use of tocolytic treatment for inhibiting preterm labour/The WHO Reproductive Health Library. Geneva: World Health Organization, 2015. URL: https:// /pregnancy-cornplications/preterm-birth/who-recommendation-use-tocolytic-treatment-inhibiting-preterm-labour).
18. Yoneda S, Yoneda N, Fukuta K, et al. In which preterm labor-patients is intravenous maintenance tocolysis effective? J Obstet Gynaecol Res 2018; 44: 397-407. DOI: 10.1111 /jog. 13547.
19. Morfaw F, Fundoh M, Bartoszko J, et al. Using tocolysis in pregnant women with symptomatic placenta praevia does not significantly improve prenatal, perinatal, neonatal and maternal outcomes: a systematic review and meta-analysis. Syst Rev 2018; 7 (1): 249. DOI: 10.1186/s13643-018-0923-2.
20. Ding MX, Luo X, Zhang XM, et al. Progesterone and nifedipine for maintenance tocolysis after arrested preterm labor: A systematic review and meta-analysis of randomized controlled trial. Taiwan J Obstet Gynecol 2016; 55 (3): 399-404. DOI: 10.1016/j. tjog. 2015.07.005.
21. Miyazaki C, Garcia RM, Ota E, et al. Tocolysis for inhibiting preterm birth in extremely preterm birth, multiple gestations and in growth-restricted fetuses: a systematic review and meta-analysis. Reproductive Health 2016; 13 (1): 1. URL: https://doi.Org/10.1186/s12978-015-0115-7.
22. Wood S, Rabi Y, Tang S, et al. Progesterone in women with arrested premature labor, a report of a randomised clinical trial and updated meta-analysis. ВМС Pregnancy Childbirth 2017; 17 (1): 258. DOI: 10.1186/s12884-017-1400-y.
23. Ohhashia M, Yoshitomib T, Sumiyoshia K, et al. Magnesium sulphate and perinatal mortality and morbidity in very-low-birthweight infants born between 24 and 32 weeks of gestation in Japan. European Journal of Obstetrics and Gynecology and Reproductive Biology 2016; 201: 140-5. URL: https://doi.Org/10.1016/j. ejogrb. 2016.03.048.
24. Shepherd E, Salam RA, Middleton P, et al. Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev 2017; 8 (8): CD012077. DOI: 10.1002/14651858. CD012077. pub2.
25. Brookfield KF, Elkomy M, Su F, et al. Optimization of maternal magnesium sulfate administration for fetal neuroprotection: application of a prospectively constructed pharmacokinetic model to the beam cohort. The Journal of Clinical Pharmacology 2017; 57 (11): 1419-24. DOI: 10.1002/jcph. 941.
26. Brookfield KF, Vinson A. Magnesium sulfate use for fetal neuroprotection. Curr Opin Obstet Gynecol 2019; 31 (2): 110-5. DOI: 10.1097/GCO. 0000000000000529.
27. Berger R, Su,der S. Neuroprotection in preterm infants. Biomed Res Int 2015; 2015:257139. DOI: 10.1155/2015/257139.
28. Zeng X, Xue Y, Tian Q, et al. Effects and safety of magnesium sulfate on neuroprotection: a meta-analysis based on prisma guidelines. Medicine (Baltimore) 2016; 95 (1): 2451. DOI: 10.1097/MD. 0000000000002451.
29. De Silva ML, Sawchuck DA, Synnes D, et al. No. 376-Magnesium sulphate for fetal neuroprotection. J Obstet and Gynaecol Can 2019; 419 (4): 505-22. URL: https:// jogc. 2018.09.018.
30. Marret S, Ancel P-Y. Protection cerebrale de I'enfant ne premature par le sulfate de magnesium. La Revue Sage-Femme 2017; 16 (4): 262-78. URL: https://doi.Org/10.1016/j. jgyn. 2016.09.028.
31. Bachnas AM, Akbar IAM, Dachlan GE, et al. The role of magnesium sulfate (MgS04) in fetal neuroprotection. J Matern Fetal Neonatal Med 2019; 15: 1-361. DOI: 10.1080/14767058.2 019.1619688.
32. Meller CH, Izbizky G, Otaco L. Update on the use of magnesium sulphate for fetal neuroprotection in preterm birth. Arch Argent Pediatr 2015; 113 (4): 345-51. DOI: 10.5546/aap. 2015.345.
33. Vilchez G, Dai J, Lagos M, et al. Maternal side effects & fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial. J Matern Fetal Neonatal Med 2018; 31 (2): 178-83. DOI: 10.1080/ 14767058.2017.1279143. Epub 2017 Jan 23.
34. Doyle LW, Anderson PJ, Haslam R, et al. School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA 2014; 312 (11): 1105-13. DOI: 10.1001/jama. 2014.11189.
35. Thinkhamrop J, Hofmeyr GJ, Adetoro O, et al. Antibiotic prophylaxis during the second and third trimester to reduce adverse pregnancy outcomes and morbidity. Cochrane Database Syst Rev2015; 1: CD002250. DOI: 10.1002/14651858. CD002250. pub2.
36. Kayem G, Lorthe E, Doret M. Management of preterm labor. J Gynecol Obstet Biol Reprod (Paris) 2016; 45 (10): 1364-73. DOI: 10.1016/j. jgyn. 2016.09.029. Epub 2016 Oct 24.
37. Yoneda S, Shiozaki A, Yoneda N, et al. Antibiotic therapy increases the risk of preterm birth in preterm labor without intra-amniotic microbes, but may prolong the gestation period in preterm labor with microbes, evaluated by rapid and high-sensitive PCR system. Am J Reprod Immunol 2016; 75 (4): 440-50. DOI: 10.1111/aji. 12484. Epub 2016 Jan 18.
38. Brabant G. Bacterial vaginosis and spontaneous preterm birth. J Gynecol Obstet Biol Reprod (Paris) 2016; 45 (10): 1247-60. DOI: 10.1016/j. jgyn. 2016.09.014. Epub 2016 Oct 26.

2020_01_017-023.pdf309.84 KB

No votes yet